Theravance Biopharma Inc (TBPH)
8.48
+0.05
(+0.59%)
USD |
NASDAQ |
Jun 18, 16:00
8.49
+0.01
(+0.12%)
After-Hours: 20:00
Theravance Biopharma Cash from Investing (Quarterly): 17.03M for March 31, 2024
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 17.03M |
| December 31, 2023 | -0.677M |
| September 30, 2023 | -0.021M |
| June 30, 2023 | 11.05M |
| March 31, 2023 | -43.05M |
| December 31, 2022 | 39.16M |
| September 30, 2022 | 1.075B |
| June 30, 2022 | 7.515M |
| March 31, 2022 | 31.92M |
| December 31, 2021 | 10.82M |
| September 30, 2021 | -35.79M |
| June 30, 2021 | 35.77M |
| March 31, 2021 | 113.70M |
| December 31, 2020 | 52.37M |
| September 30, 2020 | 66.54M |
| June 30, 2020 | -176.59M |
| March 31, 2020 | 68.40M |
| December 31, 2019 | 14.06M |
| September 30, 2019 | -23.66M |
| June 30, 2019 | -1.296M |
| March 31, 2019 | -72.16M |
| December 31, 2018 | 99.39M |
| September 30, 2018 | 46.65M |
| Date | Value |
|---|---|
| June 30, 2018 | 41.96M |
| March 31, 2018 | -11.29M |
| December 31, 2017 | 41.25M |
| September 30, 2017 | 14.76M |
| June 30, 2017 | 11.18M |
| March 31, 2017 | -123.52M |
| December 31, 2016 | -46.20M |
| September 30, 2016 | -49.84M |
| June 30, 2016 | -68.58M |
| March 31, 2016 | 16.38M |
| December 31, 2015 | -34.50M |
| September 30, 2015 | 62.09M |
| June 30, 2015 | 41.30M |
| March 31, 2015 | 42.15M |
| December 31, 2014 | 9.684M |
| September 30, 2014 | -109.86M |
| June 30, 2014 | -4.459M |
| March 31, 2014 | -1.62M |
| December 31, 2013 | -1.066M |
| September 30, 2013 | -0.237M |
| June 30, 2013 | -0.691M |
| March 31, 2013 | -0.64M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-176.59M
Minimum
Jun 2020
1.075B
Maximum
Sep 2022
63.13M
Average
12.55M
Median
Cash from Investing (Quarterly) Benchmarks
| Zoetis Inc | -131.00M |
| Corcept Therapeutics Inc | -9.014M |
| Nektar Therapeutics | 19.26M |
| Stereotaxis Inc | 0.00 |
| Cara Therapeutics Inc | 25.95M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -1.022M |
| Cash from Financing (Quarterly) | -1.716M |
| Free Cash Flow | -18.44M |
| Free Cash Flow Per Share (Quarterly) | -0.0231 |
| Free Cash Flow to Equity (Quarterly) | -1.113M |
| Free Cash Flow to Firm (Quarterly) | -1.113M |
| Free Cash Flow Yield | -4.21% |